{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:34:47Z","timestamp":1773956087523,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1194694"],"award-info":[{"award-number":["GNT1194694"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijantimicag.2025.107684","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T07:59:49Z","timestamp":1764575989000},"page":"107684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of ibuprofen on the pharmacokinetics of intravenous flucloxacillin in healthy adults"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9093-3992","authenticated-orcid":false,"given":"Alison","family":"Boast","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8228-1536","authenticated-orcid":false,"given":"Amy","family":"Legg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1368-8356","authenticated-orcid":false,"given":"Stephen YC","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6545-9408","authenticated-orcid":false,"given":"Stephen","family":"Duffull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4016-8986","authenticated-orcid":false,"given":"Amanda","family":"Gwee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2025.107684_bib0001","first-page":"766","article-title":"Bioavailability and half-life of two preparations of flucloxacillin","volume":"95","author":"Paton","year":"1982","journal-title":"N Z Med J"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0002","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of beta-lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0003","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1111\/bcp.14887","article-title":"Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid","volume":"87","author":"Drennan","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/archinte.1955.00250070099012","article-title":"Probenecid (Benemid): its uses and side-effects in 2,502 patients","volume":"95","author":"Boger","year":"1955","journal-title":"AMA Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.xphs.2020.09.004","article-title":"Drug metabolites potently inhibit renal organic anion transporters OAT1 and OAT3","volume":"110","author":"Zou","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0006","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1021\/mp300365t","article-title":"Potent inhibitors of human organic anion transporters 1 and 3 from clinical drug libraries: discovery and molecular characterization","volume":"9","author":"Duan","year":"2012","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0007","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1248\/bpb.b16-00970","article-title":"Inhibition of methotrexate uptake via organic anion transporters OAT1 and OAT3 by glucuronides of nonsteroidal anti-inflammatory drugs","volume":"40","author":"Iwaki","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0008","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijantimicag.2018.11.018","article-title":"Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen","volume":"53","author":"Wilkes","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0009","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40262-018-0667-0","article-title":"Choosing the allometric exponent in covariate model building","volume":"58","author":"Sinha","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2125.1975.tb01566.x","article-title":"Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis","volume":"2","author":"Nauta","year":"1975","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0012","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/dmd.112.049569","article-title":"Organic anion transporter 3 interacts selectively with lipophilic beta-lactam antibiotics","volume":"41","author":"Wolman","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0013","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0022-3565(24)34949-3","article-title":"The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1","volume":"290","author":"Jariyawat","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0014","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/fcp.12541","article-title":"Differential interactions of the beta-lactam cloxacillin with human renal organic anion transporters (OATs)","volume":"34","author":"Lalanne","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0015","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2125.2008.03266.x","article-title":"Inhibition of flucloxacillin tubular renal secretion by piperacillin","volume":"66","author":"Landersdorfer","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0016","article-title":"Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function","volume":"11","author":"Bell","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0017","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/jac\/dkaa187","article-title":"Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations","volume":"75","author":"Jager","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0018","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1128\/AAC.01410-06","article-title":"Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin","volume":"51","author":"Landersdorfer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0019","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/ckj\/sfaa059","article-title":"Acute kidney injury following prophylactic flucloxacillin and gentamicin in primary hip and knee arthroplasty","volume":"14","author":"Graham","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0020","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/jac\/dkq184","article-title":"Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics","volume":"65","author":"Ulldemolins","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0021","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkae207","article-title":"Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection","volume":"79","author":"Hermann","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0022","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C9 and nonsteroidal anti-inflammatory drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2025.107684_bib0023","unstructured":"CPIC. CPIC guideline for NSAIDs based on CYP2C9 genotype, https:\/\/cpicpgx.org\/guidelines\/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype\/.1st November 2025"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925002390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925002390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:17:32Z","timestamp":1773940652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857925002390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0924857925002390"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107684","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of ibuprofen on the pharmacokinetics of intravenous flucloxacillin in healthy adults","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107684"}}